A Potential Breakthrough: Argenx Reports Positive Phase 2 Results for Celiac Disease Treatment FB102
On October 8, 2026, the global immunology company argenx announced a significant milestone in the therapeutic landscape for celiac disease. Top-line results from its Phase 2 clinical trial of FB102,…







